Roth Capital Analysts Give Biopharmx Corp (BPMX) a $3.00 Price Target

Roth Capital set a $3.00 price objective on Biopharmx Corp (NASDAQ:BPMX) in a research report released on Thursday morning. The brokerage currently has a buy rating on the stock.

Biopharmx Corp (NASDAQ:BPMX) opened at 0.4211 on Thursday. Biopharmx Corp has a 1-year low of $0.19 and a 1-year high of $1.60. The stock’s market cap is $28.52 million. The stock has a 50 day moving average of $0.43 and a 200 day moving average of $0.48.

Biopharmx Corp (NASDAQ:BPMX) last released its earnings results on Tuesday, December 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. Equities analysts expect that Biopharmx Corp will post ($0.55) earnings per share for the current year.

“Roth Capital Analysts Give Biopharmx Corp (BPMX) a $3.00 Price Target” was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are reading this article on another publication, it was copied illegally and republished in violation of US and international trademark & copyright law. The legal version of this article can be read at http://sleekmoney.com/roth-capital-analysts-give-biopharmx-corp-bpmx-a-3-00-price-target/1661725.html.

In other news, Director Stephen Morlock bought 428,571 shares of Biopharmx Corp stock in a transaction on Monday, November 28th. The shares were bought at an average cost of $0.35 per share, for a total transaction of $149,999.85. Following the acquisition, the director now owns 543,956 shares in the company, valued at $190,384.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

5 Day Chart for NASDAQ:BPMX

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/roth-capital-analysts-give-biopharmx-corp-bpmx-a-3-00-price-target/1661725.html

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *